Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solriamfetol in Parkinson's Disease with Excessive Sleepiness
NCT03037203Phase 2Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jan 2017
- Primary completion
- Aug 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of solriamfetol in Parkinson's disease (PD), sponsored by Jazz Pharmaceuticals plc. Started Jan 2017; status: completed.
02
Drugs
solriamfetol
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03037203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03037203.